Regorafenib and trifluridine/tipiracil for previously treated metastatic colorectal cancer

Published on 04 Jan 2022
Last Updated on 19 Dec 2022

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has recommended:

• Regorafenib 40 mg tablet for treating metastatic colorectal cancer that has been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and if RAS wild-type, an anti-EGFR therapy.

Subsidy status

Regorafenib 40 mg tablet is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication with effect from 4 January 2022.

MAF assistance does not apply to any formulations or strengths of trifluridine/tipiracil.

Clinical indications, subsidy class and MediShield Life claim limits for both drugs are provided in the Annex.

Regorafenib and trifluridine/tipiracil for previously treated metastatic colorectal cancer (Updated 19 December 2022) [PDF, 131 KB]

PES Treatments for metastatic colorectal cancer (Updated 19 December 2022) [PDF, 79 KB]